13:43 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample and mouse studies suggest inhibiting MUC5B polymerization could help treat pulmonary fibrosis. In lung samples from IPF patients, epithelial cell levels of MUC5B, which forms polymeric gels in alveoli, and...
08:00 , Jan 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Infectious disease Mucin 5B oligomeric mucus/gel-forming (MUC5B) Mouse studies suggest maintaining baseline MUC5B expression is necessary to promote the clearance of pathogens from respiratory...
07:00 , Jun 20, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary disease Mucin 5B oligomeric mucus/gel-forming (MUC5B) Patient studies suggest the rs35705950 SNP in the MUC5B promoter region could be a marker of interstitial...
07:00 , May 5, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Mucin 5B oligomeric mucus/gel-forming (MUC5B) A study in patients suggests that MUC5B could be a risk marker of...